Literature DB >> 17626111

Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.

A F Shorr1, J L Wainright, C S Cors, C J Lettieri, S D Nathan.   

Abstract

Pulmonary hypertension (PH) may complicate idiopathic pulmonary fibrosis (IPF) but the prevalence of PH in IPF remains undefined. The present authors sought to describe the prevalence of PH in IPF. The lung transplant registry for the USA (January 1995 to June 2004) was analysed and IPF patients who had undergone right heart catheterisation (RHC) were identified. PH was defined as a mean pulmonary arterial pressure ((Ppa)) > or =25 mmHg and severe PH as a (Ppa) >40 mmHg. Independent factors associated with PH were determined. Of the 3,457 persons listed, 2,525 (73.0%) had undergone RHC. PH affected 46.1% of subjects; approximately 9% had severe PH. Variables independently associated with mild-to-moderate PH were as follows: need for oxygen, pulmonary capillary wedge pressure (P(pcw)) and forced expiratory volume in one second (FEV(1)). Independent factors related to severe PH included the following: carbon dioxide tension, age, FEV(1), P(pcw), need for oxygen and ethnicity. A sensitivity analysis in subjects with P(pcw) <15 mmHg did not appreciably alter the present findings. Pulmonary hypertension is common in idiopathic pulmonary fibrosis patients awaiting lung transplant, but the elevations in mean pulmonary arterial pressure are moderate. Lung volumes alone do not explain the pulmonary hypertension. Given the prevalence of pulmonary hypertension and its relationship with surrogate markers for quality of life (e.g. activities of daily living), future trials of therapies for this may be warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626111     DOI: 10.1183/09031936.00107206

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  79 in total

1.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

2.  Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension.

Authors:  Harry Karmouty-Quintana; Kemly Philip; Luis F Acero; Ning-Yuan Chen; Tingting Weng; Jose G Molina; Fayong Luo; Jonathan Davies; Ngoc-Bao Le; Isabelle Bunge; Kelly A Volcik; Thanh-Thuy T Le; Richard A Johnston; Yang Xia; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2014-10-15       Impact factor: 5.191

3.  The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study.

Authors:  Takahiro Sato; Ichizo Tsujino; Ayako Sugimoto; Toshitaka Nakaya; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satoshi Konno; Noriko Oyama-Manabe; Masaharu Nishimura
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

4.  MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor β inducing fibrotic responses.

Authors:  Javier Milara; Beatriz Ballester; M J Safont; Enrique Artigues; Juan Escrivá; Esteban Morcillo; Julio Cortijo
Journal:  Mucosal Immunol       Date:  2020-09-04       Impact factor: 7.313

5.  Clinical characteristics of pulmonary hypertension in bronchiectasis.

Authors:  Lan Wang; Sen Jiang; Jingyun Shi; Sugang Gong; Qinhua Zhao; Rong Jiang; Ping Yuan; Bigyan Pudasaini; Jing He; Zhicheng Jing; Jinming Liu
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

6.  Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.

Authors:  Robert M Jackson; Marilyn K Glassberg; Carol F Ramos; Pablo A Bejarano; Ghazwan Butrous; Orlando Gómez-Marín
Journal:  Lung       Date:  2009-12-12       Impact factor: 2.584

7.  Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients.

Authors:  Maha K Ghanem; Hoda A Makhlouf; Gamal R Agmy; Hisham M K Imam; Doaa A Fouad
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

Review 8.  New perspectives on management of idiopathic pulmonary fibrosis.

Authors:  Silvia Puglisi; Sebastiano Emanuele Torrisi; Virginia Vindigni; Riccardo Giuliano; Stefano Palmucci; Massimiliano Mulè; Carlo Vancheri
Journal:  Ther Adv Chronic Dis       Date:  2016-02-01       Impact factor: 5.091

9.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

10.  Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension?

Authors:  Kamonpun Ussavarungsi; Augustine S Lee; Charles D Burger
Journal:  Oman Med J       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.